Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial and Operating Results

REGULATED INFORMATION Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial and Operating Results FDA PMA Application Review Nearing Conclusion Positioned for U.S. Commercial Launch in March 2025 Mont-Saint-Guibert, Belgium – March 13, 2024, 7:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the fourth quarter and financial year 2024. Recent Financial and Operating Highlights Revenue for the fourth quarter of 2024 was €1.3 million, which excludes €0.6 million of deferred […]

Ministry of Justice Invites Public Consultation on 2025 Budget Law

Ramallah: In a significant step towards promoting transparency and public participation, the Ministry of Justice has published the draft of the Public Budget Law for 2025 on its official electronic platform, known as the “Legislation Platform.” This i…

Search

General News